EQT Life Sciences
EQT Life Sciences is a European venture capital firm (division of EQT AB) investing 10-60M EUR per deal across biotech therapeutics, MedTech, diagnostics, and healthtech globally, managing approximately 3.5 billion EUR across 12 funds and three specialized investment strategies.
- Company typePrivate
- Founded1996
- HeadquartersAmsterdam, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
What EQT Life Sciences does
EQT Life Sciences is one of Europe's largest dedicated life sciences venture capital and private equity firms, operating as a division of Stockholm-based EQT AB. Founded in 1996 as LSP (Life Sciences Partners) and rebranded under the EQT brand following acquisition by EQT Group, the firm is headquartered in Amsterdam with offices across key life sciences hubs. With approximately €3.5 billion raised across 12 private funds and a 30+ person investment team comprising medical, scientific, and industry experts, EQT Life Sciences invests 10-60 million EUR per deal across therapeutics, medical devices, diagnostics, and healthtech globally.
The firm operates three distinct investment strategies: Life Sciences Funds (LSP 1-7) focused on biotech drug development at all stages, Health Economic Funds targeting later-stage MedTech, Digital Health, and Diagnostics, and the LSP Dementia Fund dedicated to neurodegenerative disease investments. Each strategy is led by a dedicated partner (René R. Kuijten for Life Sciences, Rudy Dekeyser for Health Economics, Philip Scheltens for Dementia). Beyond capital, the firm provides portfolio companies with strategic, clinical, operational, financial, and commercial guidance, supported by an ecosystem of co-investors including Frazier Life Sciences, RA Capital, Wellington Management, Forbion, Gimv, and Sanofi Ventures.
EQT Life Sciences generates revenue through traditional fund management economics: recurring management fees on committed and deployed capital across its 12 funds, supplemented by carried interest from portfolio exits. The firm's track record includes 150+ private company investments over 30 years and marquee realizations including Amolyt Pharma (to AstraZeneca), Neuravi (to Johnson & Johnson), Tubulis (up to $5B to Gilead), ImCheck Therapeutics (up to €1B to Ipsen), and Vivasure Medical (to Haemonetics). The firm actively invests across Europe and the United States, with current portfolio of 65+ companies spanning oncology, CNS/neuroscience, respiratory, metabolic, and rare disease areas.
EQT Life Sciences firmographics
Firmographics- Name
- EQT Life Sciences
- Legal name
- EQT Life Sciences (operating division of EQT AB)
- Website
- https://lspvc.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EQT Life Sciences is a European venture capital firm (division of EQT AB) investing 10-60M EUR per deal across biotech therapeutics, MedTech, diagnostics, and healthtech globally, managing approximately 3.5 billion EUR across 12 funds and three specialized investment strategies.
- Ownership category
- akta.pro rank
EQT Life Sciences industry classification
Industry- Product category
- Venture Capital and Private Equity (Life Sciences)
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where EQT Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
EQT Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management Fees: Management fees earned from managing 12 private funds across 3 investment strategies totaling approximately 3.5 billion EUR in capital raised.
- Carry/Performance Fees: Carried interest from successful portfolio company exits and realizations, including exits such as Tubulis to Gilead ($5B), ImCheck Therapeutics to Ipsen (up to EUR 1B), Vivasure Medical to Haemonetics, and Amolyt Pharma.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
EQT Life Sciences product offering
Product offeringCore offering
EQT Life Sciences is a venture capital and private equity firm that invests growth capital into innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. It manages approximately 3.5 billion EUR across 12 private funds in three investment strategies (Life Sciences Funds LSP 1-7, Health Economic Funds, and the Dementia Fund), typically investing 10-60 million EUR per deal alongside strategic, clinical, operational, financial, and commercial guidance for portfolio companies.
Product overview
EQT Life Sciences is an investment firm offering three distinct investment strategies managed across 12 private funds: Life Sciences Funds (LSP 1-7) for biotech drug development at all stages, Health Economic Funds for later-stage MedTech/Digital Health/Diagnostics focus, and the LSP Dementia Fund for neurodegenerative disease investments. The firm provides not only capital (investment range of 10-60M EUR) but also strategic, clinical, operational, financial, and commercial guidance to support portfolio companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Life Sciences Funds (LSP 1-7) Biotech-focused investment funds covering drug development at all stages, targeting innovative therapeutic companies globally with investment range of 10-60M EUR per deal.
- Health Economic Funds Later-stage investment funds focusing on MedTech, Digital Health, and Diagnostics companies to enhance care quality and reduce healthcare costs.
- LSP Dementia Fund Specialized investment fund for drug development and medical technology targeting neurodegenerative diseases including Alzheimer's and other forms of dementia.
Quantifiable outcome
- 30-year track record investing in life sciences
- +3 more outcomes
Companies that use EQT Life Sciences
Customer profileSegments4 records
Ideal customer profiles2 records
EQT Life Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EQT Life Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- HCA HealthcaremajorStrategic partnership with Cyted Health for US market expansion through clinical deployment.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
EQT Life Sciences competitors and assessment
Company assessmentDirect peers
- Forbion: European life sciences venture capital firm managing multiple funds across biotech and MedTech; frequently co-invests with EQT Life Sciences (e.g., Mosanna Therapeutics Series A) and targets the same therapeutic and European geographies.
- Sofinnova Partners: One of the largest European life sciences VC firms with a multi-strategy approach (Crossover, Industrial Biotech, MedTech); co-invested with EQT Life Sciences in Neurent Medical Series C and competes for similar European biotech deals.
- Atlas Venture: US- and UK-based early-stage life sciences VC firm that builds biotech companies from inception; co-investor with EQT Life Sciences (e.g., Kinaset Therapeutics) and a comparable specialist in therapeutics-focused venture investing.
- Frazier Life Sciences: US-based life sciences investment firm (part of Frazier Healthcare Partners); co-led the RQ Bio $115M Series A with EQT Life Sciences and pursues a similar public-and-private biotech strategy.
- RA Capital Management: Boston-based multi-stage investment manager focused on healthcare and life sciences; led the Kinaset Therapeutics $103M Series B alongside EQT Life Sciences and is a direct competitor for biotech deal flow.
- HealthCap: Stockholm-based European life sciences VC firm investing across therapeutic stages; highly comparable Nordic-European competitor with similar strategy focus and exits profile.
- Novo Holdings (Novo Ventures): Copenhagen-based holding company of the Novo Nordisk Foundation with a dedicated life sciences venture arm; one of Europe's largest life sciences investors with similar late-stage biotech and therapeutic focus.
- Pivotal bioVenture Partners: US-based life sciences VC firm; co-led the Mosanna Therapeutics $80M Series A with EQT Life Sciences and a key shareholder in Evommune's IPO — directly comparable biotech-focused venture investor.
- MVM Partners: Boston- and London-based healthcare-focused growth equity firm; led the Neurent Medical €62.5M Series C and is a closely comparable transatlantic life sciences growth investor.
Regional players
- Gimv: Belgian-listed investment company with a dedicated Health & Care platform; co-led Exciva's €51M Series B with EQT Life Sciences and a frequent co-investor in European healthcare deals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EQT Life Sciences social profiles
Digital presenceEQT Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
EQT Life Sciences leadership team
Management profileNumber of profiles
Profiles9 records
EQT Life Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EQT Life Sciences M&A and investment
M&A and investmentM&A
Investments198 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EQT Life Sciences
What does EQT Life Sciences do?
EQT Life Sciences is a venture capital and private equity firm that invests growth capital into innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. It manages approximately 3.5 billion EUR across 12 private funds in three investment strategies (Life Sciences Funds LSP 1-7, Health Economic Funds, and the Dementia Fund), typically investing 10-60 million EUR per deal alongside strategic, clinical, operational, financial, and commercial guidance for portfolio companies.
Is EQT Life Sciences a public or private company?
EQT Life Sciences is a private company. It is classified as private equity controlled and is currently operating.
When was EQT Life Sciences founded?
EQT Life Sciences was founded in 1996. It employs 11 to 50 people.
Where is EQT Life Sciences based?
EQT Life Sciences is headquartered in Amsterdam, Netherlands, in the Europe region.
How does EQT Life Sciences make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carry/Performance Fees.
Who are EQT Life Sciences's main competitors?
Direct peers on record are Forbion, Sofinnova Partners, Atlas Venture, Frazier Life Sciences, RA Capital Management, HealthCap, Novo Holdings (Novo Ventures), Pivotal bioVenture Partners and MVM Partners. Gimv is listed as a regional player.
Does EQT Life Sciences have an API?
No public API is recorded for EQT Life Sciences.
What industry is EQT Life Sciences in?
EQT Life Sciences's product category is Venture Capital and Private Equity (Life Sciences). Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.